Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:

Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04843098
• Other study ID #: TL-117-202001
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: April 2021
• Est. completion date: January 2024

Study information

• Verified date: April 2021
• Source: Suzhou Junde Biotechnology Co., Ltd
• Contact: Ye Guo, Dr
• Phone: 021-38804518
• Email: pattrickguo[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.

Description:

This is a Phase 1/2 open label, single arm study, and is divided into three phases: the single-agent dose-escalation phase Ia trial, the TL117 plus paclitaxel dose-escalation phase Ib trial, and the open label, multicenter phase 2 trial of TL117 plus paclitaxel.

Adverse events and dose limiting toxicities will be assessed from the first dose of study drug though day 28. When the maximum tolerated dose (MTD) of TL117 plus paclitaxel is determined, additional patients will be treated at the defined RP2D dose until occurrence of unacceptable toxicity, disease progression or withdrawal of consent or death.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 108
• Est. completion date: January 2024
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18-70 years old for Phase 1a, 18-75 years old for Phase 1b and 2;

2. Histologically and/or cytologically confirmation of recurrent/metastatic squamous cell carcinoma of the head and neck;

3. At least one evaluable or measurable tumor lesion;

4. Adequate performance status;

5. A minimum life expectancy of > 3 months;

6. Adequate cardiac, kidney, and liver function;

7. Willingness of all subjects of childbearing potential to use acceptable methods of birth control;

Exclusion Criteria:

1. Any chemotherapy, radiotherapy, targeted therapy, immunotherapy, endocrine therapy and other systematic anti-tumor therapies within 4 weeks prior to the first dose of the study drug (some exceptions apply)

2. Prior or current PI3K inhibitor therapy;

3. Type 1 or type 2 diabetes requiring antihyperglycemic medication;

4. Major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the first dose, or required elective surgery during the study period;

5. Any unresolved toxicities from prior therapy greater than Grade 1;

6. Inability to swallow, or serious gastrointestinal absorption conditions;

7. History of immunodeficiency;

8. Active central nervous system metastases;

9. Active hepatitis B or C virus infection;

10. Uncontrolled active infection;

11. Serious cardiovascular disease;

12. Clinically uncontrollable effusion in the third space;

13. Known allergy and/or contraindications to paclitaxel;

14. Known alcohol or drug dependence;

15. Mental disorders or poor compliance;

16. Pregnant or lactating women;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• TL117
TL117 capsules orally once daily
• Paclitaxel
Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Suzhou Junde Biotechnology Co., Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase Ia -Dose Limiting Toxicity (DLT) of TL117 treatment	Per DLT criteria as defined in protocol	From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
Primary	Phase Ib -Dose Limiting Toxicity (DLT) of TL117 plus paclitaxel combination treatment	Per DLT criteria as defined in protocol	From time of the first dosing to time of Cycle 1 Day 28(each cycle is 28 days)
Primary	Phase II - Objective response rate (ORR)	Objective response rate (ORR): percentage of patients with best overall response of complete response (CR) and partial response (PR) according to RECIST v1.1.	Every 8 weeks from date of first treatment until date of last treatment up to 12 months